New vaccines have been licensed in the US to protect adults age 60 years and older from respiratory syncytial virus (RSV). In this episode of the Schaffner Report, William Schaffner, MD, medical director of the National Foundation for Infectious Diseases (NFID) talks with NFID Executive Director and CEO Marla Dalton, CAE, about the new RSV vaccines for adults.
Learn more at: www.nfid.org
